Multimodal Analgesia in Breast Surgical Procedures: Technical and Pharmacological Considerations for Liposomal Bupivacaine Use

Anoushka M. Afonso, Martin I. Newman, Neil Seeley, Jacob L Hutchins, Kevin L. Smith, Gabriel Mena, Jesse C. Selber, Michel H. Saint-Cyr, Jeffrey C. Gadsden

Research output: Contribution to journalArticlepeer-review

9 Scopus citations

Abstract

Enhanced recovery after surgery is a multidisciplinary perioperative clinical pathway that uses evidence-based interventions to improve the patient experience as well as increase satisfaction, reduce costs, mitigate the surgical stress response, accelerate functional recovery, and decrease perioperative complications. One of the most important elements of enhanced recovery pathways is multimodal pain management. Herein, aspects relating to multimodal analgesia following breast surgical procedures are discussed with the understanding that treatment decisions should be individualized and guided by sound clinical judgment. A review of liposomal bupivacaine, a prolonged-release formulation of bupivacaine, in the management of postoperative pain following breast surgical procedures is presented, and technical guidance regarding optimal administration of liposomal bupivacaine is provided.

Original languageEnglish (US)
Article numbere1480
JournalPlastic and Reconstructive Surgery - Global Open
Volume5
Issue number9
DOIs
StatePublished - Sep 1 2017

Bibliographical note

Funding Information:
Disclosure: Funding was not provided to the authors for the development of this article. Under author direction, editorial and medical writing assistance was provided by Michael D. Morren, RPh, MBA, of Peloton Advantage, LLC, supported by Pacira Pharmaceuticals, Inc., the manufacturer of liposomal bupivacaine. Dr. Afonso has received research funding from Pacira Pharmaceuticals, Inc. Dr. Newman is a paid consultant and speaker for Novadaq Technologies Inc. and Pacira Pharmaceuticals, Inc. Dr. Seeley is a consultant for Pacira Pharmaceuticals, Inc. and speaker for Edwards Lifesciences. Dr. Hutchins is a member of the speakers bureau for Halyard Health and is a consultant for and has received research funding from Pacira Pharmaceuticals, Inc. Dr. Smith is a paid consultant and speaker for Allergan and Pacira Pharmaceuticals, Inc. and a consultant for VitaThreads, LLC. Dr. Mena is an expert consultant for Pacira Pharmaceuticals, Inc. and Edwards Lifesciences. Dr. Selber has received a one-time consulting fee from Pacira Pharmaceuticals, Inc. for participation in a focus group. Dr. Saint-Cyr is a consultant for Pacira Pharmaceuticals, Inc. Dr. Gadsden is a consultant for B. Braun Medical Inc. The Article Processing Charge was paid for by Peloton Advantage, LLC.

Funding Information:
Under author direction, editorial and medical writing assistance was provided by Michael D. Morren, RPh, MBA, of Peloton Advantage, LLC, supported by Pacira Pharmaceuticals, Inc., the manufacturer of liposomal bupivacaine. The authors were fully responsible for the content, editorial decisions, and opinions expressed in the current article. All authors were involved in the critical revision and review of the article text and figures, as well as approval of the final draft for submission. The authors did not receive an honorarium related to the development of this article.

Publisher Copyright:
© 2017 The Authors.

Copyright:
Copyright 2017 Elsevier B.V., All rights reserved.

Fingerprint Dive into the research topics of 'Multimodal Analgesia in Breast Surgical Procedures: Technical and Pharmacological Considerations for Liposomal Bupivacaine Use'. Together they form a unique fingerprint.

Cite this